医学
肿瘤科
内科学
危险系数
肺癌
生物标志物
多元分析
比例危险模型
倾向得分匹配
混淆
生存分析
置信区间
生物
生物化学
作者
Tao Zhang,Wei Xue,Daquan Wang,Kuo Xu,Lizhong Wu,Yuqi Wu,Zongmei Zhou,Dongfu Chen,Qiang Feng,Jun Liang,Zefen Xiao,Zhouguang Hui,Jima Lv,Xin Wang,Lei Deng,Wenqing Wang,Wenyang Liu,Jianyang Wang,Yirui Zhai,Jie Wang,Nan Bi,Lühua Wang
标识
DOI:10.1016/j.radonc.2020.12.039
摘要
Background Baseline lung immune prognostic index (LIPI) was reported as a potential predictive biomarker of immune checkpoint inhibitor treatment and a prognostic biomarker for metastatic non-small cell lung cancer (NSCLC). However, it remains unclear whether LIPI is associated with outcomes in locally advanced NSCLC (LA-NSCLC). Materials/methods Patients with LA-NSCLC receiving radiotherapy between 2000 to 2017 were retrospectively reviewed. Based on pretreatment dNLR and LDH level made up LIPI per previous publications, patients were divided into good group (0 score) and intermediate-poor group (1 or 2 scores). Propensity score matching (PSM) was conducted to balance confounding variables. Results A total of 1079 patients were eligible for analysis. Patients with intermediate-poor pretreatment LIPI had inferior overall survival (OS), progression-free survival (PFS), locoregional relapse-free survival (LRRFS), and distant metastasis-free survival (DMFS) than those with good LIPI. Multivariate analysis suggested that LIPI was an independent prognostic marker for OS (hazard ratio [HR] = 1.19, 95% CI: 1.02–1.40), PFS (HR = 1.18, 95% CI: 1.02–1.36), and LRRFS (HR = 1.22, 95% CI: 1.05–1.41) in patients with inoperable LA-NSCLC. PSM analysis further verified that intermediate-poor LIPI was an independent prognostic factor for shorter survivals (OS, PFS and LRRFS). Conclusions LIPI is a simple and promising prognostic marker for patients with unresectable LA-NSCLC. Further prospected studies are warranted to validated these findings.
科研通智能强力驱动
Strongly Powered by AbleSci AI